Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated:  1/18/2018
Dana-Farber Cancer Inst
mi
from
Boston, MA
Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated: 1/18/2018
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated:  1/18/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated: 1/18/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated:  1/18/2018
Local Institution
mi
from
Villejuif Cedex,
Phase I Biomarker Study (BMS-936558)
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Status: Enrolling
Updated: 1/18/2018
Local Institution
mi
from
Villejuif Cedex,
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Hot Springs, AZ
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Hot Springs, AZ
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Washington,
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Orlando, FL
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Detroit, MI
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Pascagoula, MS
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Kansas City, MO
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Omaha, NE
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Lebanon, NH
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Gettysburg, PA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Hershey, PA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Pawtucket, RI
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Round Rock, TX
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Rx for Better Breast Health
Prescription for Better Breast Health
Status: Enrolling
Updated:  1/18/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Rx for Better Breast Health
Prescription for Better Breast Health
Status: Enrolling
Updated: 1/18/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Status: Enrolling
Updated:  1/18/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Status: Enrolling
Updated: 1/18/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit: A Randomized Controlled Trial
Status: Enrolling
Updated:  1/18/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit: A Randomized Controlled Trial
Status: Enrolling
Updated: 1/18/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
Status: Enrolling
Updated:  1/18/2018
Baylor College of Medicine
mi
from
Houston, TX
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
Status: Enrolling
Updated: 1/18/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
1200.43.00113 Boehringer Ingelheim Investigational Site
mi
from
Harvey, IL
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
1200.43.00113 Boehringer Ingelheim Investigational Site
mi
from
Harvey, IL
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
1200.43.00106 Boehringer Ingelheim Investigational Site
mi
from
Peoria, IL
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
1200.43.00106 Boehringer Ingelheim Investigational Site
mi
from
Peoria, IL
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Omaha, NE
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
1200.131.00179 Boehringer Ingelheim Investigational Site
mi
from
Stony Brook, NY
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
1200.131.00179 Boehringer Ingelheim Investigational Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated:  1/19/2018
1200.131.05451 Boehringer Ingelheim Investigational Site
mi
from
Ciudad Autonoma de Bs As,
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Status: Enrolling
Updated: 1/19/2018
1200.131.05451 Boehringer Ingelheim Investigational Site
mi
from
Ciudad Autonoma de Bs As,
Click here to add this to my saved trials
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma
Status: Enrolling
Updated:  1/19/2018
Orlando Health
mi
from
Orlando, FL
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma
Status: Enrolling
Updated: 1/19/2018
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma
Status: Enrolling
Updated:  1/19/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma
Status: Enrolling
Updated: 1/19/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated:  1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated: 1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated:  1/19/2018
BioKinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated: 1/19/2018
BioKinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
A Pilot Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated:  1/19/2018
BioKinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
A Pilot Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions
Status: Enrolling
Updated: 1/19/2018
BioKinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen
Status: Enrolling
Updated:  1/22/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen
Status: Enrolling
Updated: 1/22/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen
Status: Enrolling
Updated:  1/22/2018
The Mayo Clinic
mi
from
Rochester, MN
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen
Status: Enrolling
Updated: 1/22/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Status: Enrolling
Updated:  1/22/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Status: Enrolling
Updated: 1/22/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver
Status: Enrolling
Updated:  1/22/2018
Northwestern University
mi
from
Chicago, IL
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver
Status: Enrolling
Updated: 1/22/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
University of Texas/MD Anderson Cancer Center MD Anderson PSC
mi
from
Houston, TX
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
University of Texas/MD Anderson Cancer Center MD Anderson PSC
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
Karmanos Cancer Institute Study Coordinator
mi
from
Detroit, MI
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
Karmanos Cancer Institute Study Coordinator
mi
from
Detroit, MI
Click here to add this to my saved trials